Status:
TERMINATED
Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
Lead Sponsor:
Radboud University Medical Center
Conditions:
Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
For esophageal cancer that can not be removed by surgery, the choice of treatment is a combination of chemotherapy and radiotherapy. We call this combination- (or concurrent) chemoradiotherapy. Chemot...
Detailed Description
A complete response rate of approximately 30% is achieved for standard treatment of irresectable carcinoma of the oesophagus, consisting of concurrent chemoradiation therapy (50.5 Gy + cisplatin/5-FU)...
Eligibility Criteria
Inclusion
- Age 18 - 70years
- Histology proven SCC or adenocarcinoma of the oesophagus
- No proven (distant) metastases (ultrasonography, CT or MRI)
- No prior treatment for carcinoma of the oesophagus
- Karnofsky performance status ≥70% (appendix A)
- Irresectable disease as assessed by the multidisciplinary tumour board
- All patients (male and female) must use effective contraception methods according to CPMP/ICH/286/95 if of reproductive potential (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the whole duration of the study and until six months after they received the last treatment dose
- No contraindications for cytotoxic therapy or panitumumab:
- No known hypersensitivity/allergy to any of the compounds used
- Haematology: Neutrophil count ≥ 1.5∙109 /L Thrombocyte count ≥ 100∙109 /L Haemoglobin ≥ 6.2 mmol/L (100 g/L)
- No known HIV infection or other condition of persistent immunodeficiency
- Renal function:
- Creatinine clearance (MDRD) ≥ 60 mL/min
- Hepatic function:
- Total bilirubin ≤ 1.5∙ULN
- AST, ALT, AP ≤ 2.5∙ULN
- Electrolyte balance:
- (albumin corrected) calcium ≤ 2.87 mmol/L (=11.5 mg/dl) but ≥ lower limit of normal (LLN)
- Magnesium ≥ LLN
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- No known other serious illness or medical condition present at entry in the study including: Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4 Clinically significantly abnormal electrocardiogram (ECG) or left ventricular ejection fraction (LVEF) below the institutional ULN
- Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment/randomisation
- Significant neurologic or psychiatric disorders
- Active uncontrolled infection Active disseminated intravasal coagulation
- Symptomatic peripheral neuropathy (CTCAE v3.0 term "neuropathy: sensory") ≥ grade 2 Ototoxicity (CTCAE v3.0 any term in "auditory/ear") ≥ grade 2 except if due to trauma or mechanical impairment due to tumour mass
- Other serious underlying medical condition which could impair the ability of the patient to participate in the study No or insufficient oral nutrient intake
- No prior exposure to EGFR pathway targeting agents
- No known drug abuse
- Absence of any psychological, familial, sociological (e.g. severe alcohol addiction expected to hamper protocol compliance) or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- No participation in another interventional clinical trial in the preceding 30 days
- Written informed consent to participate to study must be given according to ICH/GCP, and national/local regulations.
Exclusion
- Prior treatment for this tumour
- Prior treatment with radiation therapy in the area of the oesophagus or other site that will interfere with proposed treatment
- Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
- History of other prior malignancy in past 5 years, other than basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.
- Exclusion criteria for the PET-scan (secondary endpoint)
- For the PET-scan the following exclusion criteria are used:
- Severe claustrophobia
- Diabetes mellitus (type I and II)
- Serum glucose level \>11 mmol/L
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01262183
Start Date
January 1 2011
End Date
October 1 2012
Last Update
May 11 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Centre Nijmegen
Nijmegen, Gelderland, Netherlands, 6500 HB